Article

Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress.

Centre for Clinical Neuroscience Research, Stavanger University Hospital, Stavanger, Norway.
Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 4.87). 02/2007; 78(1):36-42. DOI: 10.1136/jnnp.2005.083113
Source: PubMed

ABSTRACT To explore the profile of neuropsychiatric symptoms in patients with dementia associated with Parkinson's disease (PDD).
537 patients with PDD drawn from an international multicentre clinical trial of rivastigmine were assessed using the 10-item Neuropsychiatric Inventory (NPI). A cluster analysis was used to investigate the inter-relationship of NPI items. Associations between the clusters and demographic and clinical variables were analysed.
89% of the patients presented at least one symptom on the NPI, 77% had two or more symptoms and 64% had at least one symptom with a score > or = 4. The most common symptoms were depression (58%), apathy (54%), anxiety (49%) and hallucinations (44%). Patients with more severe dementia and advanced Parkinson's disease had more neuropsychiatric symptoms. Nearly 60% of the care givers reported at least one NPI symptom to be of at least moderate severe distress. Five NPI clusters were identified: one group with few and mild symptoms (52%); a mood cluster (11%, high scores on depression, anxiety and apathy); apathy (24%; high apathy and low scores on other items); agitation (5%, high score on agitation and high total NPI score); and a psychosis cluster (8%; high scores on delusions and hallucinations). The psychosis and agitation clusters had the lowest Mini-Mental State Examination score and the highest Unified Parkinson's Disease Rating Scale and care giver distress scores.
Neuropsychiatric symptoms are common in patients with PDD. The profile of these symptoms differs from that in other types of dementia. Subgroups with different neuropsychiatric profiles were identified. These subgroups may be associated with distinct neurobiological changes, which should be explored in future studies.

0 Bookmarks
 · 
109 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Both NPS have negative effects on cognitive performance and life expectancy. The current study aimed to investigate and compare monoaminergic etiologies between both neurodegenerative conditions, given the lack of an efficient pharmacological treatment until present. Eleven behaviorally relevant brain regions of the left frozen hemisphere of 10 neuropathologically confirmed AD patients with/without depression (AD + D/-D; 5 were psychotic within AD + D), 10 confirmed DLB patients, all of whom were depressed (DLB + D; 5 psychotic patients), and, finally, 10 confirmed control subjects were regionally dissected. All patients were retrospectively assessed before death using the Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD) and Cornell Scale for Depression in Dementia amongst others. The concentrations of dopamine (DA), serotonin (5-HT), (nor)adrenaline and respective metabolites, i.e. 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), 5-hydroxy-3-indoleacetic acid (5-HIAA), and, 3-methoxy-4-hydroxyphenylglycol (MHPG), were determined using reversed-phase high-performance liquid chromatography with electrochemical detection. DLB subjects had the overall lowest monoamine and metabolite concentrations regarding 33 out of 41 significant monoaminergic group alterations. Moreover, MHPG levels were significantly decreased in almost 8 out of 11 brain regions of DLB- compared to AD patients. We also observed the lowest 5-HT and 5-HIAA levels, and 5-HIAA/5-HT turnover ratios in DLB + D compared to AD + D subjects. Additionally, a 4- and 7-fold increase of DOPAC/DA and HVA/DA turnover ratios, and, a 10-fold decrease of thalamic DA levels in DLB + D compared to AD + D patients and control subjects was noticed. Regarding psychosis, hippocampal DA levels in the overall DLB group significantly correlated with Behave-AD AB scores. In the total AD group, DA levels and HVA/DA ratios in the amygdala significantly correlated with Behave-AD AB scores instead. Monoaminergic neurotransmitter alterations contribute differently to the pathophysiology of depression and psychosis in DLB as opposed to AD, with a severely decreased serotonergic neurotransmission as the main monoaminergic etiology of depression in DLB. Similarly, psychosis in DLB might, in part, be etiologically explained by dopaminergic alterations in the hippocampus, whereas in AD, the amygdala might be involved.
    Alzheimer's Research and Therapy 02/2015; 7(7). · 3.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Resumo: A doença de Alzheimer (DA) tem como expressão fundamental a demência enquanto a do-ença de Parkinson (DP) apresenta manifestações essencialmente motoras neuropsi-quiátrico. Houve diferenças significativas entre os grupos DA,DP e GC em relação a 6 comportamen-tos. Na comparação direta entre os grupos DA e DP houve diferença significativa em relação a 2 questões e entre os grupos DP e GC em relação a 4 questões. Os resultados obtidos podem ser de extrema rele-vância na condução da terapêutica e reabilitação in-dividuais dos pacientes. Palavras-chave: Parkinson; Alzheimer; comporta-mento. Área do Conhecimento: Ciências da Saúde – Medi-cina – CNPq. 1. INTRODUÇÃO À medida que a expectativa de vida torna-se mais elevada, sobretudo nos países desenvolvidos e em desenvolvimento, tem-se observado um crescimento da prevalência de doenças neurodegenerativas, tais como a doença de Alzheimer (DA) e a doença de Parkinson (DP), acompanhadas de intensas reper-cussões biopsicossociais. A DA é a principal causa de demência, a qual é defi-nida como uma síndrome clínica caracterizada declí-nio cognitivo e/ou comportamental crônico e geral-mente progressivo, de início insidioso. A DP, por sua vez, cursa com manifestações essen-cialmente motoras, tais como tremor de repouso, rigidez muscular, bradicinesia e anormalidade postu-ral. No entanto, a ocorrência de distúrbios cognitivos é frequente, e a prevalência média de demência está em torno de 31% [1, 37]. O Inventário Neuropsiquiátrico (INP) foi desenvolvido para avaliar dez distúrbios comportamentais que po-dem ocorrer em pacientes acometidos por doenças neurodegenerativas: delírios, alucinações, agita-ção/agressão, disforia, ansiedade, euforia, apatia, desinibição, irritabilidade/labilidade, agitação motora [14]. É composto por dez questões, tendo cada uma o conteúdo referente a um dos dez comportamentos citados. A informação é obtida através do acompanhante do paciente, o qual é questionado a classificar o com-portamento de acordo com sua gravidade (ausente, discreto, moderado/grave) e de acordo com sua fre-quência de acometimento (ausente, ocasional, maior ou igual uma vez por semana). O INP é fonte importante de informações sobre o estado psicológico e comportamental do paciente, ambos determinantes do percurso clínico da doença, da melhor abordagem terapêutica a ser utilizada e, consequentemente, da saúde do cuidador. O objetivo desse estudo é comparar os sintomas comportamentais e neuropsiquiátricos nas doenças de Alzheimer e de Parkinson.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Apathy, characterized by lack of motivation and loss of initiative, is a non-cognitive symptom that affects a high proportion, but not all, of patients with all forms of dementia. To explore the phenomenon of apathy in people with dementia, we searched the PubMed and Google Scholar electronic databases for original research and review articles on apathetic behaviors in patients with dementia using the search terms "apathy, behavioral and psychological symptoms, dementia, Alzheimer's disease, Frontotemporal dementia, Dementia associated with Parkinson's disease, Huntington's disease, Vascular dementia". Some nosological aspects, neurobiological basis, and assessment of, as well as, potential benefits of non-pharmacologic and pharmacologic interventions for apathy in dementia are discussed. Greater understanding of apathy will improve the identification, intervention, and treatment of this ubiquitous and pernicious syndrome.
    Journal of Nervous & Mental Disease 10/2014; 202(10):718-724. · 1.81 Impact Factor

Full-text (2 Sources)

Download
55 Downloads
Available from
Jun 2, 2014